Music recommendation algorithms were supposed to help us cut through the noise, but they just served us up slop.

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...